| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | filamin binding | 7.53e-08 | 29 | 153 | 6 | GO:0031005 | |
| GeneOntologyMolecularFunction | benzodiazepine receptor binding | 4.36e-06 | 5 | 153 | 3 | GO:0030156 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 1.98e-05 | 149 | 153 | 8 | GO:1990782 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 2.62e-05 | 23 | 153 | 4 | GO:0034235 | |
| GeneOntologyMolecularFunction | neurohypophyseal hormone activity | 5.83e-05 | 2 | 153 | 2 | GO:0005185 | |
| GeneOntologyMolecularFunction | calcium ion binding | PADI4 PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 ZZEF1 RYR2 UMODL1 LRP2 EEF2K DSG4 PCDH10 UNC13A CDH12 PADI1 | 6.33e-05 | 749 | 153 | 17 | GO:0005509 |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 1.29e-04 | 34 | 153 | 4 | GO:0015125 | |
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 1.51e-04 | 14 | 153 | 3 | GO:0005130 | |
| GeneOntologyMolecularFunction | V1A vasopressin receptor binding | 1.74e-04 | 3 | 153 | 2 | GO:0031894 | |
| GeneOntologyMolecularFunction | vasopressin receptor binding | 3.46e-04 | 4 | 153 | 2 | GO:0031893 | |
| GeneOntologyMolecularFunction | epidermal growth factor binding | 3.46e-04 | 4 | 153 | 2 | GO:0048408 | |
| GeneOntologyMolecularFunction | calmodulin binding | 4.05e-04 | 230 | 153 | 8 | GO:0005516 | |
| GeneOntologyMolecularFunction | glycolipid binding | 5.37e-04 | 49 | 153 | 4 | GO:0051861 | |
| GeneOntologyMolecularFunction | protein-arginine deiminase activity | 5.75e-04 | 5 | 153 | 2 | GO:0004668 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 1.39e-03 | 29 | 153 | 3 | GO:0035325 | |
| GeneOntologyBiologicalProcess | homophilic cell adhesion via plasma membrane adhesion molecules | PSG6 PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 CEACAM7 CEACAM8 PCDHB8 CLSTN1 CEACAM1 DSG4 MPZL2 PCDH10 CDH12 | 1.04e-10 | 187 | 151 | 14 | GO:0007156 |
| GeneOntologyBiologicalProcess | cell-cell adhesion via plasma-membrane adhesion molecules | PSG6 PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 CEACAM7 CEACAM8 PCDHB8 CLSTN1 ELFN2 CEACAM1 PTPRS DSG4 MPZL2 PCDH10 CDH12 | 1.31e-09 | 313 | 151 | 16 | GO:0098742 |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 2.61e-06 | 14 | 151 | 4 | GO:0070348 | |
| GeneOntologyBiologicalProcess | cell growth | PAPPA2 ERBB2 AVP PI16 PSG6 CEACAM7 CEACAM8 CLSTN1 CEACAM1 KMT2D EGFR PTPRS TRPV2 PLXNA4 EIF2AK4 UNC13A USP47 | 3.46e-06 | 625 | 151 | 17 | GO:0016049 |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 3.54e-06 | 15 | 151 | 4 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 3.54e-06 | 15 | 151 | 4 | GO:1903387 | |
| GeneOntologyBiologicalProcess | cell-cell adhesion | HFE MAGI1 ERBB2 SH2B3 PSG6 PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 CEACAM7 CEACAM8 PCDHB8 CLSTN1 ELFN2 CEACAM1 EGFR PTPRS PKHD1 DSG4 MPZL2 FBLIM1 PCDH10 CDH12 | 3.68e-06 | 1077 | 151 | 23 | GO:0098609 |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 4.69e-06 | 16 | 151 | 4 | GO:0038016 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 4.74e-06 | 91 | 151 | 7 | GO:0030193 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 5.49e-06 | 93 | 151 | 7 | GO:1900046 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 6.10e-06 | 17 | 151 | 4 | GO:0070342 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 6.10e-06 | 17 | 151 | 4 | GO:1901143 | |
| GeneOntologyBiologicalProcess | regulation of cell growth | PAPPA2 ERBB2 AVP PI16 PSG6 CEACAM7 CEACAM8 CLSTN1 CEACAM1 EGFR PTPRS TRPV2 PLXNA4 UNC13A USP47 | 6.55e-06 | 519 | 151 | 15 | GO:0001558 |
| GeneOntologyBiologicalProcess | regulation of coagulation | 6.78e-06 | 96 | 151 | 7 | GO:0050818 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 7.80e-06 | 18 | 151 | 4 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 1.14e-05 | 69 | 151 | 6 | GO:0030195 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 1.22e-05 | 20 | 151 | 4 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 1.24e-05 | 70 | 151 | 6 | GO:1900047 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 1.46e-05 | 72 | 151 | 6 | GO:0050819 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 1.50e-05 | 21 | 151 | 4 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 1.50e-05 | 21 | 151 | 4 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 1.50e-05 | 21 | 151 | 4 | GO:0002838 | |
| GeneOntologyBiologicalProcess | regulation of growth | PAPPA2 ERBB2 HIF1A AVP PI16 PSG6 CEACAM7 CEACAM8 CLSTN1 CEACAM1 SPTBN4 EGFR PTPRS TRPV2 PLXNA4 AHR UNC13A USP47 | 1.59e-05 | 777 | 151 | 18 | GO:0040008 |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 2.19e-05 | 23 | 151 | 4 | GO:0090331 | |
| GeneOntologyBiologicalProcess | phosphatidylinositol 3-kinase/protein kinase B signal transduction | ERBB2 SH2B3 PSG6 CEACAM7 CEACAM8 GRM2 HPSE CEACAM1 EGFR PKHD1 LRP2 FGR | 2.55e-05 | 382 | 151 | 12 | GO:0043491 |
| GeneOntologyBiologicalProcess | feeding behavior | 2.61e-05 | 162 | 151 | 8 | GO:0007631 | |
| GeneOntologyBiologicalProcess | regulation of wound healing | 3.11e-05 | 166 | 151 | 8 | GO:0061041 | |
| GeneOntologyBiologicalProcess | regulation of response to wounding | 3.25e-05 | 217 | 151 | 9 | GO:1903034 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 3.31e-05 | 83 | 151 | 6 | GO:0002707 | |
| GeneOntologyBiologicalProcess | regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | ERBB2 SH2B3 PSG6 CEACAM7 CEACAM8 GRM2 HPSE CEACAM1 EGFR PKHD1 FGR | 3.65e-05 | 334 | 151 | 11 | GO:0051896 |
| GeneOntologyBiologicalProcess | negative regulation of response to wounding | 4.00e-05 | 126 | 151 | 7 | GO:1903035 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 4.25e-05 | 27 | 151 | 4 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 4.93e-05 | 28 | 151 | 4 | GO:0034111 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 7.45e-05 | 31 | 151 | 4 | GO:0010544 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 7.51e-05 | 96 | 151 | 6 | GO:0002704 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 8.41e-05 | 61 | 151 | 5 | GO:0060259 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 8.43e-05 | 98 | 151 | 6 | GO:0061045 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 8.46e-05 | 32 | 151 | 4 | GO:0070341 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 9.57e-05 | 33 | 151 | 4 | GO:2000252 | |
| GeneOntologyBiologicalProcess | growth | PAPPA2 ERBB2 HIF1A AVP PI16 PSG6 CEACAM7 CEACAM8 CLSTN1 PTGFRN CEACAM1 SPTBN4 KMT2D EGFR PTPRS LPA TRPV2 PLXNA4 AHR EIF2AK4 UNC13A USP47 | 9.64e-05 | 1235 | 151 | 22 | GO:0040007 |
| GeneOntologyBiologicalProcess | insulin metabolic process | 1.21e-04 | 35 | 151 | 4 | GO:1901142 | |
| GeneOntologyBiologicalProcess | regulation of anatomical structure morphogenesis | ERBB2 HIF1A NRDC SH2B3 PSG6 MYO19 CEACAM7 CEACAM1 NFATC3 PTPRS LPA TRPV2 PLXNA4 PKHD1 EEF2K FGR FBLIM1 UNC13A PLXNA2 ZMYM6 | 1.39e-04 | 1090 | 151 | 20 | GO:0022603 |
| GeneOntologyBiologicalProcess | neuromuscular junction development | 1.42e-04 | 68 | 151 | 5 | GO:0007528 | |
| GeneOntologyBiologicalProcess | negative regulation of cell activation | 1.46e-04 | 264 | 151 | 9 | GO:0050866 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 1.64e-04 | 15 | 151 | 3 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 1.64e-04 | 15 | 151 | 3 | GO:0002859 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 1.68e-04 | 38 | 151 | 4 | GO:2000345 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 1.74e-04 | 71 | 151 | 5 | GO:0002347 | |
| GeneOntologyBiologicalProcess | ERBB signaling pathway | 1.80e-04 | 160 | 151 | 7 | GO:0038127 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 1.86e-04 | 39 | 151 | 4 | GO:0045717 | |
| GeneOntologyBiologicalProcess | response to calcium ion | 1.87e-04 | 161 | 151 | 7 | GO:0051592 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 1.98e-04 | 73 | 151 | 5 | GO:0042304 | |
| GeneOntologyBiologicalProcess | vascular process in circulatory system | 2.29e-04 | 344 | 151 | 10 | GO:0003018 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 2.43e-04 | 17 | 151 | 3 | GO:0038158 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 2.49e-04 | 42 | 151 | 4 | GO:0090330 | |
| GeneOntologyBiologicalProcess | positive regulation of nervous system development | HIF1A NRDC CLSTN1 LIG4 OXT EGFR TRPV2 PLXNA4 LRP2 EEF2K PLXNA2 | 2.64e-04 | 418 | 151 | 11 | GO:0051962 |
| GeneOntologyBiologicalProcess | cell junction organization | COL4A5 ERBB2 PSG6 CEACAM7 PCDHB8 ALS2 CLSTN1 ELFN2 CEACAM1 SPTBN4 ACE2 OXT PTPRS PLXNA4 PKHD1 EEF2K UNC13A CDH12 | 2.82e-04 | 974 | 151 | 18 | GO:0034330 |
| GeneOntologyBiologicalProcess | behavior | HIF1A AVP PSG6 CEACAM7 CEACAM8 ALS2 GRM2 ZZEF1 ABCA7 CEACAM1 SPTBN4 ACE2 OXT EGFR EIF2AK4 ANKFN1 BBS12 | 2.91e-04 | 891 | 151 | 17 | GO:0007610 |
| GeneOntologyBiologicalProcess | maternal aggressive behavior | 3.16e-04 | 4 | 151 | 2 | GO:0002125 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 3.26e-04 | 45 | 151 | 4 | GO:0048521 | |
| GeneOntologyBiologicalProcess | import into cell | HFE GAPVD1 CD300LF PSG6 CEACAM7 CEACAM8 SLC12A8 SLC39A10 HPSE ABCA7 CEACAM1 ACE2 ZFYVE9 TRPV2 LRP2 EEF2K CD302 FGR IL2RB | 3.27e-04 | 1074 | 151 | 19 | GO:0098657 |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 3.55e-04 | 46 | 151 | 4 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 3.55e-04 | 46 | 151 | 4 | GO:0072574 | |
| GeneOntologyBiologicalProcess | endocytosis | HFE GAPVD1 CD300LF PSG6 CEACAM7 CEACAM8 HPSE ABCA7 CEACAM1 ACE2 ZFYVE9 LRP2 EEF2K CD302 FGR IL2RB | 3.79e-04 | 827 | 151 | 16 | GO:0006897 |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 3.85e-04 | 47 | 151 | 4 | GO:0015721 | |
| GeneOntologyBiologicalProcess | cell surface receptor protein tyrosine kinase signaling pathway | DOCK3 COL4A5 ERBB2 HIF1A SH2B3 PSG6 CEACAM7 CEACAM8 SHC4 TIPARP CEACAM1 TXNIP EGFR CPNE3 FGR | 3.95e-04 | 747 | 151 | 15 | GO:0007169 |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte activation | 3.98e-04 | 240 | 151 | 8 | GO:0002695 | |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 4.03e-04 | 85 | 151 | 5 | GO:1903670 | |
| GeneOntologyBiologicalProcess | enzyme-linked receptor protein signaling pathway | DOCK3 HFE COL4A5 ERBB2 HIF1A SH2B3 PSG6 CEACAM7 CEACAM8 SHC4 TIPARP CEACAM1 LEFTY2 TXNIP ZFYVE9 EGFR CPNE3 LRP2 DSG4 FGR | 4.19e-04 | 1186 | 151 | 20 | GO:0007167 |
| GeneOntologyBiologicalProcess | regulation of body fluid levels | 4.23e-04 | 442 | 151 | 11 | GO:0050878 | |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 4.25e-04 | 86 | 151 | 5 | GO:0042058 | |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 4.49e-04 | 87 | 151 | 5 | GO:0001974 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 4.53e-04 | 49 | 151 | 4 | GO:0002837 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 4.53e-04 | 49 | 151 | 4 | GO:0072576 | |
| GeneOntologyBiologicalProcess | negative regulation of cell adhesion | 4.53e-04 | 375 | 151 | 10 | GO:0007162 | |
| GeneOntologyBiologicalProcess | cell morphogenesis | SEMA6B ERBB2 NRDC ALS2 SPTBN4 EGFR PTPRS TRPV2 PLXNA4 PKHD1 AHR LRP2 EEF2K EIF2AK4 FGR FBLIM1 UNC13A CDH12 PLXNA2 ZMYM6 | 4.57e-04 | 1194 | 151 | 20 | GO:0000902 |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 4.89e-04 | 50 | 151 | 4 | GO:0002834 | |
| GeneOntologyBiologicalProcess | response to 2,3,7,8-tetrachlorodibenzodioxine | 5.25e-04 | 5 | 151 | 2 | GO:1904612 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 5.35e-04 | 22 | 151 | 3 | GO:0030853 | |
| GeneOntologyBiologicalProcess | epidermal growth factor receptor signaling pathway | 5.63e-04 | 139 | 151 | 6 | GO:0007173 | |
| GeneOntologyBiologicalProcess | semaphorin-plexin signaling pathway | 5.69e-04 | 52 | 151 | 4 | GO:0071526 | |
| GeneOntologyBiologicalProcess | regulation of ERBB signaling pathway | 6.09e-04 | 93 | 151 | 5 | GO:1901184 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 6.12e-04 | 53 | 151 | 4 | GO:0034110 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 6.12e-04 | 23 | 151 | 3 | GO:0002858 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 6.95e-04 | 24 | 151 | 3 | GO:0002855 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 6.95e-04 | 24 | 151 | 3 | GO:2001214 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 6.95e-04 | 24 | 151 | 3 | GO:0002420 | |
| GeneOntologyBiologicalProcess | regulation of nervous system development | HIF1A NRDC CLSTN1 TG LIG4 OXT EGFR PTPRS TRPV2 PLXNA4 LRP2 EEF2K PLXNA2 | 7.03e-04 | 625 | 151 | 13 | GO:0051960 |
| GeneOntologyBiologicalProcess | tissue remodeling | 7.09e-04 | 262 | 151 | 8 | GO:0048771 | |
| GeneOntologyBiologicalProcess | liver development | 7.32e-04 | 202 | 151 | 7 | GO:0001889 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 7.54e-04 | 56 | 151 | 4 | GO:0002418 | |
| GeneOntologyBiologicalProcess | regulation of vasoconstriction | 7.73e-04 | 98 | 151 | 5 | GO:0019229 | |
| GeneOntologyBiologicalProcess | B-1 B cell homeostasis | 7.83e-04 | 6 | 151 | 2 | GO:0001922 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 7.86e-04 | 25 | 151 | 3 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 7.86e-04 | 25 | 151 | 3 | GO:0002423 | |
| GeneOntologyBiologicalProcess | hepaticobiliary system development | 7.98e-04 | 205 | 151 | 7 | GO:0061008 | |
| GeneOntologyBiologicalProcess | circulatory system development | ERBB2 HIF1A THSD7A SH2B3 PI16 PSG6 SPEG CEACAM7 BCOR HPSE RYR2 TIPARP CEACAM1 LEFTY2 ALDH1A2 OXT EGFR NFATC3 LPA PLXNA4 AHR LRP2 | 8.23e-04 | 1442 | 151 | 22 | GO:0072359 |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte activation | 9.45e-04 | 211 | 151 | 7 | GO:0051250 | |
| GeneOntologyBiologicalProcess | blood circulation | HIF1A AVP PSG6 CEACAM7 RYR2 CEACAM1 SPTBN4 ACE2 OXT EGFR LPA AHR KNG1 | 9.79e-04 | 648 | 151 | 13 | GO:0008015 |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 9.79e-04 | 60 | 151 | 4 | GO:0045922 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 4.69e-06 | 16 | 153 | 4 | GO:0070021 | |
| GeneOntologyCellularComponent | cell surface | HFE NRDC PSG6 CEACAM7 CEACAM8 CLSTN1 ZZEF1 LY6G6C RS1 PTGFRN ABCA7 CEACAM1 ACE2 EGFR UMODL1 LPA TRPV2 PKHD1 LRP2 CD302 LY9 IL2RB | 2.00e-05 | 1111 | 153 | 22 | GO:0009986 |
| GeneOntologyCellularComponent | apical plasma membrane | PAPPA2 ERBB2 PSG6 CEACAM7 CEACAM8 CA14 SLC39A10 ABCA7 CEACAM1 ACE2 EGFR PKHD1 LRP2 | 6.28e-05 | 487 | 153 | 13 | GO:0016324 |
| GeneOntologyCellularComponent | semaphorin receptor complex | 1.04e-04 | 13 | 153 | 3 | GO:0002116 | |
| GeneOntologyCellularComponent | apical part of cell | PAPPA2 HFE ERBB2 PSG6 CEACAM7 CEACAM8 CA14 SLC39A10 ABCA7 CEACAM1 ACE2 EGFR PKHD1 LRP2 | 1.19e-04 | 592 | 153 | 14 | GO:0045177 |
| GeneOntologyCellularComponent | external side of plasma membrane | HFE PSG6 CEACAM7 LY6G6C RS1 CEACAM1 UMODL1 LPA PKHD1 LRP2 CD302 LY9 IL2RB | 1.19e-04 | 519 | 153 | 13 | GO:0009897 |
| GeneOntologyCellularComponent | side of membrane | HFE RASA3 PSG6 CEACAM7 CEACAM8 LY6G6C RS1 RYR2 CEACAM1 UMODL1 LPA PKHD1 LRP2 CD302 LY9 IL2RB | 6.99e-04 | 875 | 153 | 16 | GO:0098552 |
| GeneOntologyCellularComponent | adherens junction | 9.71e-04 | 212 | 153 | 7 | GO:0005912 | |
| GeneOntologyCellularComponent | manchette | 1.10e-03 | 28 | 153 | 3 | GO:0002177 | |
| GeneOntologyCellularComponent | receptor complex | HFE ERBB2 PSG6 CEACAM7 CEACAM8 CEACAM1 EGFR PLXNA4 AHR LRP2 IL2RB PLXNA2 | 1.20e-03 | 581 | 153 | 12 | GO:0043235 |
| GeneOntologyCellularComponent | cell projection membrane | 1.31e-03 | 431 | 153 | 10 | GO:0031253 | |
| MousePheno | increased skeletal muscle triglyceride level | 3.14e-05 | 21 | 124 | 4 | MP:0031415 | |
| MousePheno | decreased fatty acid oxidation | 5.46e-05 | 24 | 124 | 4 | MP:0014172 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 5.77e-05 | 47 | 124 | 5 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 7.07e-05 | 49 | 124 | 5 | MP:0020948 | |
| MousePheno | increased abdominal fat pad weight | 8.84e-05 | 27 | 124 | 4 | MP:0009286 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 1.02e-04 | 28 | 124 | 4 | MP:0020950 | |
| MousePheno | decreased cellular glucose uptake | 1.03e-04 | 53 | 124 | 5 | MP:0003926 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 1.54e-04 | 31 | 124 | 4 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 1.54e-04 | 31 | 124 | 4 | MP:0008964 | |
| MousePheno | abnormal large intestine morphology | 1.73e-04 | 276 | 124 | 10 | MP:0000489 | |
| Domain | - | PAPPA2 HFE CD300LF MID2 PSG6 SPEG CEACAM7 CEACAM8 PTGFRN CEACAM1 RIMBP3 UMODL1 NFATC3 PTPRS PLXNA4 PKHD1 RIMBP3C MPZL2 LY9 RIMBP3B ANKFN1 IL2RB PLXNA2 | 4.27e-09 | 663 | 152 | 23 | 2.60.40.10 |
| Domain | Ig-like_fold | PAPPA2 HFE CD300LF MID2 PSG6 SPEG CEACAM7 CEACAM8 PTGFRN CEACAM1 RIMBP3 UMODL1 NFATC3 PTPRS PLXNA4 PKHD1 RIMBP3C MPZL2 LY9 RIMBP3B ANKFN1 IL2RB PLXNA2 | 1.38e-08 | 706 | 152 | 23 | IPR013783 |
| Domain | CADHERIN_1 | PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 DSG4 PCDH10 CDH12 | 3.59e-07 | 113 | 152 | 9 | PS00232 |
| Domain | Cadherin | PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 DSG4 PCDH10 CDH12 | 3.59e-07 | 113 | 152 | 9 | PF00028 |
| Domain | CADHERIN_2 | PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 DSG4 PCDH10 CDH12 | 3.87e-07 | 114 | 152 | 9 | PS50268 |
| Domain | - | PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 DSG4 PCDH10 CDH12 | 3.87e-07 | 114 | 152 | 9 | 2.60.40.60 |
| Domain | CA | PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 DSG4 PCDH10 CDH12 | 4.17e-07 | 115 | 152 | 9 | SM00112 |
| Domain | Cadherin-like | PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 DSG4 PCDH10 CDH12 | 4.49e-07 | 116 | 152 | 9 | IPR015919 |
| Domain | Cadherin | PCDHGA9 PCDHGA3 PCDHGA2 PCDHGA1 PCDHB8 CLSTN1 DSG4 PCDH10 CDH12 | 5.19e-07 | 118 | 152 | 9 | IPR002126 |
| Domain | Cadherin_C | 1.08e-06 | 42 | 152 | 6 | IPR032455 | |
| Domain | Cadherin_C_2 | 1.08e-06 | 42 | 152 | 6 | PF16492 | |
| Domain | FN3_dom | PAPPA2 MID2 SPEG ELFN2 RIMBP3 UMODL1 PTPRS RIMBP3C RIMBP3B ANKFN1 IL2RB | 1.16e-06 | 209 | 152 | 11 | IPR003961 |
| Domain | FN3 | PAPPA2 MID2 SPEG ELFN2 UMODL1 PTPRS RIMBP3C RIMBP3B ANKFN1 IL2RB | 2.84e-06 | 185 | 152 | 10 | SM00060 |
| Domain | Cadherin_CS | 3.03e-06 | 109 | 152 | 8 | IPR020894 | |
| Domain | FN3 | MID2 SPEG ELFN2 RIMBP3 UMODL1 PTPRS RIMBP3C RIMBP3B ANKFN1 IL2RB | 5.43e-06 | 199 | 152 | 10 | PS50853 |
| Domain | Cadherin_2 | 1.46e-05 | 65 | 152 | 6 | PF08266 | |
| Domain | Cadherin_N | 1.46e-05 | 65 | 152 | 6 | IPR013164 | |
| Domain | IPT | 6.40e-05 | 27 | 152 | 4 | SM00429 | |
| Domain | Hormone_4 | 6.58e-05 | 2 | 152 | 2 | PF00220 | |
| Domain | Hormone_5 | 6.58e-05 | 2 | 152 | 2 | PF00184 | |
| Domain | NEUROHYPOPHYS_HORM | 6.58e-05 | 2 | 152 | 2 | PS00264 | |
| Domain | Neurhyp_horm | 6.58e-05 | 2 | 152 | 2 | PD001676 | |
| Domain | Neurohypophysial_hormone_CS | 6.58e-05 | 2 | 152 | 2 | IPR022423 | |
| Domain | - | 6.58e-05 | 2 | 152 | 2 | 2.60.9.10 | |
| Domain | NH | 6.58e-05 | 2 | 152 | 2 | SM00003 | |
| Domain | TIG | 1.12e-04 | 31 | 152 | 4 | PF01833 | |
| Domain | IPT | 1.27e-04 | 32 | 152 | 4 | IPR002909 | |
| Domain | Plexin_repeat | 1.27e-04 | 32 | 152 | 4 | IPR002165 | |
| Domain | PSI | 1.27e-04 | 32 | 152 | 4 | PF01437 | |
| Domain | Cadherin_tail | 2.26e-04 | 37 | 152 | 4 | PF15974 | |
| Domain | Cadherin_CBD | 2.26e-04 | 37 | 152 | 4 | IPR031904 | |
| Domain | Neurhyp_horm | 3.91e-04 | 4 | 152 | 2 | IPR000981 | |
| Domain | Tyr_kinase_EGF/ERB/XmrK_rcpt | 3.91e-04 | 4 | 152 | 2 | IPR016245 | |
| Domain | PSI | 4.44e-04 | 44 | 152 | 4 | IPR016201 | |
| Domain | PSI | 5.27e-04 | 46 | 152 | 4 | SM00423 | |
| Domain | PAD | 6.47e-04 | 5 | 152 | 2 | PF03068 | |
| Domain | PAD_N | 6.47e-04 | 5 | 152 | 2 | PF08526 | |
| Domain | PAD_M | 6.47e-04 | 5 | 152 | 2 | PF08527 | |
| Domain | PAD | 6.47e-04 | 5 | 152 | 2 | IPR004303 | |
| Domain | PAD_C | 6.47e-04 | 5 | 152 | 2 | IPR013530 | |
| Domain | Prot_Arg_deaminase_cen_dom | 6.47e-04 | 5 | 152 | 2 | IPR013733 | |
| Domain | PAD_N | 6.47e-04 | 5 | 152 | 2 | IPR013732 | |
| Domain | V-set | 7.83e-04 | 184 | 152 | 7 | PF07686 | |
| Domain | GF_recep_IV | 9.66e-04 | 6 | 152 | 2 | PF14843 | |
| Domain | GF_recep_IV | 9.66e-04 | 6 | 152 | 2 | IPR032778 | |
| Domain | HSF_fam | 9.66e-04 | 6 | 152 | 2 | IPR027725 | |
| Domain | Ig_V-set | 1.24e-03 | 199 | 152 | 7 | IPR013106 | |
| Domain | HSF_DNA-bind | 1.35e-03 | 7 | 152 | 2 | PF00447 | |
| Domain | Recep_L_domain | 1.35e-03 | 7 | 152 | 2 | PF01030 | |
| Domain | Furin-like | 1.35e-03 | 7 | 152 | 2 | PF00757 | |
| Domain | Rcpt_L-dom | 1.35e-03 | 7 | 152 | 2 | IPR000494 | |
| Domain | HSF_DOMAIN | 1.35e-03 | 7 | 152 | 2 | PS00434 | |
| Domain | HSF_DNA-bd | 1.35e-03 | 7 | 152 | 2 | IPR000232 | |
| Domain | HSF | 1.35e-03 | 7 | 152 | 2 | SM00415 | |
| Domain | Furin-like_Cys-rich_dom | 1.35e-03 | 7 | 152 | 2 | IPR006211 | |
| Domain | - | 1.35e-03 | 7 | 152 | 2 | 3.80.20.20 | |
| Domain | Ig_E-set | 1.61e-03 | 104 | 152 | 5 | IPR014756 | |
| Domain | Semap_dom | 2.01e-03 | 31 | 152 | 3 | IPR001627 | |
| Domain | SEMA | 2.01e-03 | 31 | 152 | 3 | PS51004 | |
| Domain | Sema | 2.01e-03 | 31 | 152 | 3 | SM00630 | |
| Domain | Sema | 2.01e-03 | 31 | 152 | 3 | PF01403 | |
| Domain | Plexin_cytopl | 2.28e-03 | 9 | 152 | 2 | PF08337 | |
| Domain | Plexin_cytoplasmic_RasGAP_dom | 2.28e-03 | 9 | 152 | 2 | IPR013548 | |
| Domain | Plexin | 2.28e-03 | 9 | 152 | 2 | IPR031148 | |
| Domain | IG_LIKE | HFE CD300LF PSG6 SPEG CEACAM7 CEACAM8 PTGFRN CEACAM1 PTPRS MPZL2 LY9 | 2.31e-03 | 491 | 152 | 11 | PS50835 |
| Domain | IG | CD300LF PSG6 SPEG CEACAM7 CEACAM8 PTGFRN CEACAM1 PTPRS MPZL2 LY9 | 2.39e-03 | 421 | 152 | 10 | SM00409 |
| Domain | Ig_sub | CD300LF PSG6 SPEG CEACAM7 CEACAM8 PTGFRN CEACAM1 PTPRS MPZL2 LY9 | 2.39e-03 | 421 | 152 | 10 | IPR003599 |
| Domain | Ig-like_dom | HFE CD300LF PSG6 SPEG CEACAM7 CEACAM8 PTGFRN CEACAM1 PTPRS MPZL2 LY9 | 2.78e-03 | 503 | 152 | 11 | IPR007110 |
| Domain | VPS9 | 2.84e-03 | 10 | 152 | 2 | PS51205 | |
| Domain | VPS9 | 2.84e-03 | 10 | 152 | 2 | PF02204 | |
| Domain | VPS9 | 2.84e-03 | 10 | 152 | 2 | IPR003123 | |
| Pubmed | TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer. | 8.68e-08 | 3 | 155 | 3 | 25605021 | |
| Pubmed | 1.54e-07 | 54 | 155 | 6 | 8482578 | ||
| Pubmed | RIM-BP3 is a manchette-associated protein essential for spermiogenesis. | 3.46e-07 | 4 | 155 | 3 | 19091768 | |
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 37531413 | ||
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 28567513 | ||
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 8207827 | ||
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 11994468 | ||
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 20381490 | ||
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 22159884 | ||
| Pubmed | CEACAM2 positively regulates integrin αIIbβ3-mediated platelet functions. | 3.67e-07 | 14 | 155 | 4 | 27161904 | |
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 23070997 | ||
| Pubmed | 3.67e-07 | 14 | 155 | 4 | 10491101 | ||
| Pubmed | 4.99e-07 | 15 | 155 | 4 | 24948196 | ||
| Pubmed | 4.99e-07 | 15 | 155 | 4 | 20410265 | ||
| Pubmed | 4.99e-07 | 15 | 155 | 4 | 26586918 | ||
| Pubmed | 4.99e-07 | 15 | 155 | 4 | 16044082 | ||
| Pubmed | CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation. | 4.99e-07 | 15 | 155 | 4 | 15467833 | |
| Pubmed | Comparative DNA sequence analysis of mouse and human protocadherin gene clusters. | 6.20e-07 | 68 | 155 | 6 | 11230163 | |
| Pubmed | 6.62e-07 | 16 | 155 | 4 | 17356169 | ||
| Pubmed | 6.62e-07 | 16 | 155 | 4 | 25085348 | ||
| Pubmed | Differences in tissue-specific and embryonic expression of mouse Ceacam1 and Ceacam2 genes. | 6.62e-07 | 16 | 155 | 4 | 11284729 | |
| Pubmed | 7.17e-07 | 162 | 155 | 8 | 25826454 | ||
| Pubmed | Structure and evolution of RIM-BP genes: identification of a novel family member. | 8.63e-07 | 5 | 155 | 3 | 17855024 | |
| Pubmed | A striking organization of a large family of human neural cadherin-like cell adhesion genes. | 8.71e-07 | 72 | 155 | 6 | 10380929 | |
| Pubmed | Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. | 1.03e-06 | 74 | 155 | 6 | 10817752 | |
| Pubmed | 1.30e-06 | 77 | 155 | 6 | 10835267 | ||
| Pubmed | Large exons encoding multiple ectodomains are a characteristic feature of protocadherin genes. | 1.63e-06 | 80 | 155 | 6 | 10716726 | |
| Pubmed | Roles of semaphorin-6B and plexin-A2 in lamina-restricted projection of hippocampal mossy fibers. | 1.72e-06 | 6 | 155 | 3 | 20484647 | |
| Pubmed | COL4A5 GAPVD1 CD300LF NRDC DDX42 ALS2 G2E3 SEC31A SLC39A10 BCOR ATRNL1 CPNE3 ZBTB10 LRP2 EIF2AK4 ESPL1 UTRN XPOT | 1.80e-06 | 1084 | 155 | 18 | 11544199 | |
| Pubmed | In vivo validation of late-onset Alzheimer's disease genetic risk factors. | 4.46e-06 | 25 | 155 | 4 | 38687251 | |
| Pubmed | Semaphorin heterodimerization in cis regulates membrane targeting and neocortical wiring. | 5.26e-06 | 26 | 155 | 4 | 39152101 | |
| Pubmed | 5.99e-06 | 153 | 155 | 7 | 10718198 | ||
| Pubmed | 7.15e-06 | 28 | 155 | 4 | 8672132 | ||
| Pubmed | On and off retinal circuit assembly by divergent molecular mechanisms. | 1.85e-05 | 12 | 155 | 3 | 24179230 | |
| Pubmed | GAPVD1 MCM7 BCOR TXNIP KMT2D FAM193A RAB3GAP2 ZBTB10 LRP2 UTRN | 1.97e-05 | 418 | 155 | 10 | 34709266 | |
| Pubmed | PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells. | 1.97e-05 | 2 | 155 | 2 | 20923765 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 25349977 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 23871709 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19789263 | ||
| Pubmed | HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer. | 1.97e-05 | 2 | 155 | 2 | 23594562 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 1706616 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19946741 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 38416376 | ||
| Pubmed | Evolutionary analysis of the ErbB receptor and ligand families. | 1.97e-05 | 2 | 155 | 2 | 10824084 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 25589492 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 15143334 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 18199554 | ||
| Pubmed | Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. | 1.97e-05 | 2 | 155 | 2 | 17549377 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 27502168 | ||
| Pubmed | Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. | 1.97e-05 | 2 | 155 | 2 | 23665199 | |
| Pubmed | Epidermal growth factor receptor activity is necessary for mouse basal cell proliferation. | 1.97e-05 | 2 | 155 | 2 | 25217659 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 33896068 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 31538678 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19777609 | ||
| Pubmed | Increased concentrations of growth factors and activation of the EGFR system in breast cancer. | 1.97e-05 | 2 | 155 | 2 | 23089711 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 33260837 | ||
| Pubmed | The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. | 1.97e-05 | 2 | 155 | 2 | 34487971 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 18946768 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 27273260 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 12354693 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19954019 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 20164500 | ||
| Pubmed | Fluorescence-Raman dual modal endoscopic system for multiplexed molecular diagnostics. | 1.97e-05 | 2 | 155 | 2 | 25820115 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 23220854 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 27089381 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 33441708 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 35778545 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 20156584 | ||
| Pubmed | Loss of SPEG Inhibitory Phosphorylation of Ryanodine Receptor Type-2 Promotes Atrial Fibrillation. | 1.97e-05 | 2 | 155 | 2 | 32683896 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 20144509 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 38443188 | ||
| Pubmed | Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer. | 1.97e-05 | 2 | 155 | 2 | 17611648 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 26437915 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 12944509 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 22891338 | ||
| Pubmed | Expression of epidermal growth factor receptor and HER-2 in pediatric embryonal brain tumors. | 1.97e-05 | 2 | 155 | 2 | 20962551 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 29329808 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 32022567 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 21480528 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 21087480 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 39205824 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19287975 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 21911055 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 32931498 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 12586780 | ||
| Pubmed | Ontogeny of the vasopressin and oxytocin RNAs in the mouse hypothalamus. | 1.97e-05 | 2 | 155 | 2 | 9678638 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19180921 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 30296252 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 30610926 | ||
| Pubmed | Sociality, pathogen avoidance, and the neuropeptides oxytocin and arginine vasopressin. | 1.97e-05 | 2 | 155 | 2 | 21960250 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19672816 | ||
| Pubmed | EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. | 1.97e-05 | 2 | 155 | 2 | 25935365 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 10435588 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 19093231 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 3768139 | ||
| Pubmed | Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. | 1.97e-05 | 2 | 155 | 2 | 32917240 | |
| Pubmed | Expression of the vasopressin and oxytocin genes in human hypothalami. | 1.97e-05 | 2 | 155 | 2 | 4065330 | |
| Pubmed | EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. | 1.97e-05 | 2 | 155 | 2 | 18650488 | |
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 18182111 | ||
| Pubmed | 1.97e-05 | 2 | 155 | 2 | 17626639 | ||
| Cytoband | 5q31 | 4.68e-05 | 115 | 155 | 5 | 5q31 | |
| Cytoband | 19q13.2 | 2.48e-04 | 164 | 155 | 5 | 19q13.2 | |
| GeneFamily | Clustered protocadherins | 4.17e-05 | 64 | 109 | 5 | 20 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 5.87e-05 | 163 | 109 | 7 | 590 | |
| GeneFamily | Erb-b2 receptor tyrosine kinases | 2.14e-04 | 4 | 109 | 2 | 1096 | |
| GeneFamily | Peptidyl arginine deiminases | 3.56e-04 | 5 | 109 | 2 | 677 | |
| GeneFamily | CD molecules|V-set domain containing|Immunoglobulin like domain containing|Carcinoembryonic antigen related cell adhesion molecule family | 3.93e-04 | 24 | 109 | 3 | 906 | |
| GeneFamily | Plexins | 1.26e-03 | 9 | 109 | 2 | 683 | |
| GeneFamily | VPS9 domain containing | 1.57e-03 | 10 | 109 | 2 | 928 | |
| GeneFamily | ADAM metallopeptidase domain containing|CD molecules | 2.66e-03 | 394 | 109 | 8 | 471 | |
| GeneFamily | SH2 domain containing | 3.26e-03 | 101 | 109 | 4 | 741 | |
| GeneFamily | Zinc fingers|Zinc fingers PARP-type|Poly(ADP-ribose) polymerases | 4.62e-03 | 17 | 109 | 2 | 684 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 5.17e-03 | 18 | 109 | 2 | 91 | |
| GeneFamily | Immunoglobulin like domain containing | 6.28e-03 | 193 | 109 | 5 | 594 | |
| CoexpressionAtlas | DevelopingGonad_e12.5_ovary_emap-28876_top-relative-expression-ranked_1000 | COL4A5 GAPVD1 HIF1A MCM7 G2E3 RYR2 TIPARP FAM204A ACE2 RGL1 ALDH1A2 MECR CPNE3 GREB1 UTRN PLXNA2 XPOT ALG13 | 1.70e-05 | 804 | 151 | 18 | gudmap_developingGonad_e12.5_ovary_1000 |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#3_top-relative-expression-ranked_1000 | 2.84e-05 | 275 | 151 | 10 | gudmap_developingGonad_e14.5_ epididymis_1000_k3 | |
| CoexpressionAtlas | dev gonad_e12.5_F_VasAssMesen_MafB_k-means-cluster#1_top-relative-expression-ranked_500 | 4.74e-05 | 91 | 151 | 6 | gudmap_dev gonad_e12.5_F_VasAssMesen_MafB_k1_500 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_1000 | COL4A5 GAPVD1 DDX42 G2E3 FHIP2A TIPARP FAM204A ACE2 ALDH1A2 MECR CPNE3 EEF2K FBLIM1 PCDH10 UTRN PLXNA2 XPOT | 4.87e-05 | 790 | 151 | 17 | gudmap_developingGonad_e16.5_epididymis_1000 |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_1000 | COL4A5 GAPVD1 DDX42 G2E3 FHIP2A TIPARP FAM204A ACE2 RGL1 ALDH1A2 MECR CPNE3 PKHD1 FBLIM1 UTRN PLXNA2 XPOT | 5.77e-05 | 801 | 151 | 17 | gudmap_developingGonad_e14.5_ epididymis_1000 |
| CoexpressionAtlas | dev gonad_e12.5_F_VasAssMesen_MafB_top-relative-expression-ranked_500 | PAPPA2 MAGI1 RASA3 RYR2 TIPARP ACE2 ALDH1A2 ATRNL1 PLXNA4 TSHZ1 CDH12 | 1.08e-04 | 388 | 151 | 11 | gudmap_dev gonad_e12.5_F_VasAssMesen_MafB_500 |
| CoexpressionAtlas | Myeloid Cells, MF.Lv, CD45+ F4/80+ CD11b+, Liver, avg-2 | HFE PADI4 CD300LF PI16 HPSE CEACAM1 ZFYVE9 ATRNL1 AHR LTBR FGR | 1.47e-04 | 402 | 151 | 11 | GSM854320_500 |
| CoexpressionAtlas | DevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#3_top-relative-expression-ranked_500 | 1.56e-04 | 161 | 151 | 7 | gudmap_developingGonad_e12.5_ovary_k3_500 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_ovary_emap-9563_top-relative-expression-ranked_1000 | COL4A5 GAPVD1 HIF1A ATP8B4 G2E3 HSF5 RYR2 TIPARP FAM204A MECR CPNE3 GREB1 UTRN ZMYM6 XPOT ALG13 | 1.77e-04 | 795 | 151 | 16 | gudmap_developingGonad_e16.5_ovary_1000 |
| CoexpressionAtlas | dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_top-relative-expression-ranked_1000 | PAPPA2 MAGI1 RASA3 HPSE RYR2 TIPARP ACE2 ALDH1A2 EGFR PTPRS ATRNL1 PLXNA4 TSHZ1 MPZL2 CDH12 PLXNA2 | 1.82e-04 | 797 | 151 | 16 | gudmap_dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_1000 |
| CoexpressionAtlas | DevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_1000 | PAPPA2 COL4A5 DDX42 G2E3 FHIP2A TIPARP ALDH1A2 MECR CPNE3 PKHD1 EEF2K FBLIM1 PCDH10 UTRN PLXNA2 XPOT | 1.87e-04 | 799 | 151 | 16 | gudmap_developingGonad_e18.5_epididymis_1000 |
| CoexpressionAtlas | DevelopingGonad_e18.5_epididymis_emap-13166_k-means-cluster#3_top-relative-expression-ranked_1000 | 1.88e-04 | 281 | 151 | 9 | gudmap_developingGonad_e18.5_epididymis_1000_k3 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.38e-07 | 168 | 155 | 8 | 55f328353119cbdc521c782ebb8d163876f4186d | |
| ToppCell | wk_15-18-Epithelial-Distal_epithelial_progenitor-epi-tip_intermediate|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 2.88e-07 | 185 | 155 | 8 | 636505a3d96f75d951ab42bcf8af6ae07abc732d | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_ASM_(13)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 3.26e-07 | 188 | 155 | 8 | f54b063025d80de631382bf5326bc40aab7f7d00 | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle-Myofibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.68e-07 | 191 | 155 | 8 | b133ee1c0e58d00ddd2e4e05b01fd04947524c18 | |
| ToppCell | 10x_3'_v3-spleen_(10x_3'_v3)-myeloid-myeloid_monocytic-classical_monocyte|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.83e-07 | 198 | 155 | 8 | 74591eba5dbb2d77d416309326a26be969e4ad42 | |
| ToppCell | LPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 5.21e-07 | 200 | 155 | 8 | 8988f113708eef7d9d2a6a6c1bcfd7c8f9804d3e | |
| ToppCell | Children_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.78e-06 | 164 | 155 | 7 | e3983f655cdba308fb192182829f17bef99ce0ba | |
| ToppCell | COVID-19-Heart-CM_+_Macrophage|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.26e-06 | 170 | 155 | 7 | 3f15242a1d3e4e9871d9170b2ef05842fb609c29 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Lung_smooth_muscle-Myofibroblast|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.39e-06 | 188 | 155 | 7 | 3177b2c1723268d330d3e9f24f9e24492ace6286 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Myofibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.39e-06 | 188 | 155 | 7 | 293f2fa99f5f96aa7fd2b2a5cc94ff60eeaabe11 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 4.39e-06 | 188 | 155 | 7 | 3004e961d214919e08c7cd5f10c3de5cf85b35a3 | |
| ToppCell | RV-06._Ventricular_Cardiomyocyte_II|World / Chamber and Cluster_Paper | 4.55e-06 | 189 | 155 | 7 | 5e80c47f63980904c4c1ff02c201b67b456a0974 | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.55e-06 | 189 | 155 | 7 | 45e588b2a4ad9e3ff74e22d9d627ed3571f3b8b8 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_ASM_(13)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 4.71e-06 | 190 | 155 | 7 | 938d1f66094b1c94606e0d40213a39e5112f3322 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_myocytic|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 5.22e-06 | 193 | 155 | 7 | 000b9e6a819b94ea2e6e9173daf97ba9ac2b6cc6 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Myeloid-LYVE1+_Macrophage|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.58e-06 | 195 | 155 | 7 | c16479a10f5ca2e89aea1742dbc5cc4dc9f3ea88 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Myeloid-Macrophage-macrophage,_alveolar-Macro_c3-EREG|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.77e-06 | 196 | 155 | 7 | 80264c2fbd94418f981085fed7c5bdda1e6f404c | |
| ToppCell | 10x3'2.3-week_17-19-Myeloid_neutrophil-granulo-neutrophil|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 6.17e-06 | 198 | 155 | 7 | 82f6ac18c3a6487f03579b5c247844f1c115c2be | |
| ToppCell | 10x3'2.3-week_17-19-Myeloid_neutrophil-granulo|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 6.17e-06 | 198 | 155 | 7 | f870e398e996c1f28c8462d87b18f71b20c71011 | |
| ToppCell | 10x_3'_v3-spleen_(10x_3'_v3)-myeloid-myeloid_monocytic|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.17e-06 | 198 | 155 | 7 | 3e1e79bb7b13540a06956b59c6a62984efea19ee | |
| ToppCell | Healthy/Control-Classical_Monocyte|World / Disease group and Cell class | 6.37e-06 | 199 | 155 | 7 | 527c767a09f911e319f7ad230b6518cebc0f367d | |
| ToppCell | kidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 6.37e-06 | 199 | 155 | 7 | 174f6013af6eafa577f84205a62927f2b367fda3 | |
| ToppCell | LPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 6.59e-06 | 200 | 155 | 7 | 87827041663013f5e7273168dc8709d69840e7ce | |
| ToppCell | mild-Myeloid-CD14_Monocytes_1|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 6.59e-06 | 200 | 155 | 7 | 3874c1f078cb8789be2e2275a202357c711b1be3 | |
| ToppCell | PND10-Immune-Immune_Myeloid-Granulocytic-Neutrophil-Neutrophil_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.19e-05 | 145 | 155 | 6 | ab0e254a8d01021619853a6c175f620ccef217d8 | |
| ToppCell | PND10-Immune-Immune_Myeloid-Granulocytic-Neutrophil|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.19e-05 | 145 | 155 | 6 | 2beb4ea3838796c580076ab7769de877a3a0552c | |
| ToppCell | Children_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.74e-05 | 155 | 155 | 6 | cd7d95cbcad248670e531d80bb83c55e36ebc573 | |
| ToppCell | Frontal_cortex-Hematopoietic-MACROPHAGE|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.85e-05 | 93 | 155 | 5 | 1a112bd4e5e63826efad0338ce99d7a7ad9c72b9 | |
| ToppCell | Frontal_cortex-Hematopoietic-MACROPHAGE-MP1(C1qb)-MACROPHAGE_Macrophage.C1qb.Mrc1_(Resident_macrophage)--|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.85e-05 | 93 | 155 | 5 | 9c566fc2a8c7630bea28e8e46df55454aa409bc1 | |
| ToppCell | Frontal_cortex-Hematopoietic-MACROPHAGE-MP1(C1qb)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.85e-05 | 93 | 155 | 5 | d102a0a015a2866e3fe549ac8796b9a0d5923d7e | |
| ToppCell | Frontal_cortex-Hematopoietic-MACROPHAGE-MP1(C1qb)-MACROPHAGE_Macrophage.C1qb.Mrc1_(Resident_macrophage)-|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.85e-05 | 93 | 155 | 5 | 0967a93dcc72d2d8f12d56de186ec1af55c36001 | |
| ToppCell | Frontal_cortex-Hematopoietic-MACROPHAGE-MP1(C1qb)-MACROPHAGE_Macrophage.C1qb.Mrc1_(Resident_macrophage)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.85e-05 | 93 | 155 | 5 | 613c827a643a7b6d70ef932cfa1762e90bc5a338 | |
| ToppCell | facs-Brain_Myeloid-Striatum_-18m-Myeloid-macrophage|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.87e-05 | 157 | 155 | 6 | 9d4308312301cb922f156a7b6aededc9e1c62807 | |
| ToppCell | droplet-Spleen-nan-24m-Myeloid-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.93e-05 | 158 | 155 | 6 | e1a8dba5a88bc3ce112829c5ecb112cbbee5b078 | |
| ToppCell | droplet-Spleen-nan-24m-Myeloid|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.93e-05 | 158 | 155 | 6 | 72e4f8ae137a7dddee0dc6236532e0711065e6af | |
| ToppCell | Posterior_cortex|World / BrainAtlas - Mouse McCarroll V32 | 2.01e-05 | 159 | 155 | 6 | 18e9fe2efbe0bca7c3990f3b12b6f549e2c1263a | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c02-NCAM1|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.31e-05 | 163 | 155 | 6 | 1c014e373667be290d7fb5d24c06c6f313ac8fa3 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Epithelial-neuronal_stem_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.47e-05 | 165 | 155 | 6 | 1703d3eb644b3c743ad3c5532b1d29ea010c79c8 | |
| ToppCell | 15-Airway-Mesenchymal-Airway_Smooth_Muscle|Airway / Age, Tissue, Lineage and Cell class | 2.47e-05 | 165 | 155 | 6 | 531804467601e1ee1f771cffa21501f6d464ae10 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.47e-05 | 165 | 155 | 6 | 8a82e20c9b1156bb4bbc16f7785abb04458d671b | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting-Basal_resting_L.0.0.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.92e-05 | 170 | 155 | 6 | 0cc20322cb3e3e7bbd4daad8785c99f80e355c16 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes-Classical_monocytes_L.1.2.4.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.92e-05 | 170 | 155 | 6 | cf22a843ae2d9cd6693507fed2b7c6a45abea10e | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Airway_epithelium-respiratory_basal_cell-Basal_resting|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.92e-05 | 170 | 155 | 6 | 2d880223d01bde4bf777bd6f50b7d2768489075f | |
| ToppCell | PND07-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_mature|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.12e-05 | 172 | 155 | 6 | 584af6537685cb459bf0fc298e6f46872016c116 | |
| ToppCell | (00)_Basal-(1)_24hpi|(00)_Basal / shred by cell type and Timepoint | 3.22e-05 | 173 | 155 | 6 | a8e62e7d8baf6af691acd5c50deedbadc119ceba | |
| ToppCell | TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Non-keratinizing_Cervical_Squamous_Cell_Carcinoma-3|TCGA-Cervix / Sample_Type by Project: Shred V9 | 3.44e-05 | 175 | 155 | 6 | 0cc215109d9915af47e4d0a120ce2e46910715fa | |
| ToppCell | E18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-AM|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.55e-05 | 176 | 155 | 6 | 6548797336c9f4ca0f38e74a2c629e2a4defa252 | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.66e-05 | 177 | 155 | 6 | 065bebd22031f143e90a407f952b444a3f8818c7 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.66e-05 | 177 | 155 | 6 | b59967219f7d874805768e247c0eb2bc4d4420c8 | |
| ToppCell | facs-Marrow-Granulocytes-3m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.66e-05 | 177 | 155 | 6 | eb304f20aab075bd17aa3aef819386c0e1a235bd | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 4.15e-05 | 181 | 155 | 6 | 25915e2500430a902db37d79a749ce2990b69810 | |
| ToppCell | COVID-19-Heart-CM_+_EC_+_Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 4.15e-05 | 181 | 155 | 6 | 719eb532453ab7cd7893726885bc75d74a10b21e | |
| ToppCell | 10x5'v1-week_12-13-Myeloid_neutrophil-granulo-neutrophil-myelocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 4.28e-05 | 182 | 155 | 6 | 52eac2f892ea7f26731e0b21c578fd2665a1657a | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 4.28e-05 | 182 | 155 | 6 | ed6ae0fd8653f213fe29906a6a4e0729a62e1b75 | |
| ToppCell | droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l44-58|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.41e-05 | 183 | 155 | 6 | dc9602bed3136db91faeffef177006246dc92743 | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 4.55e-05 | 184 | 155 | 6 | 57c792e6e2fedba25d3350ffe649fd74750b579d | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-4|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 4.55e-05 | 184 | 155 | 6 | 67164bb6bcae7322cb89b585c7aa10bce35b0ecd | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 4.55e-05 | 184 | 155 | 6 | d7bd0f0c607bade67c99e9fb3578a570298bf926 | |
| ToppCell | COVID-19-Heart-CM_1|COVID-19 / Disease (COVID-19 only), tissue and cell type | 4.55e-05 | 184 | 155 | 6 | e737f0f14c49b07bbb04a165083ac32210bc5690 | |
| ToppCell | COVID-19-Heart-CM_2|COVID-19 / Disease (COVID-19 only), tissue and cell type | 4.69e-05 | 185 | 155 | 6 | 549eeb521c3985bff396ea0f202db21822efa51f | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 4.69e-05 | 185 | 155 | 6 | e58a009aaf342be019a909747b1895d5987d4daf | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 4.97e-05 | 187 | 155 | 6 | 387cb27c8a20031cd87381a9e1172f1f62e1488b | |
| ToppCell | Endothelial-Endothelial-E|Endothelial / shred on cell class and cell subclass (v4) | 5.12e-05 | 188 | 155 | 6 | 2777eb7689b271c199021fe7d9db88ccebff14de | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 5.12e-05 | 188 | 155 | 6 | c29aaae3c5bb7cd6b9b3defd4d27afde3af19ba0 | |
| ToppCell | renal_medulla_nuclei|World / Celltypes from Cells and Nuclei per compartment and clinical group | 5.28e-05 | 189 | 155 | 6 | 830d9cd0dd706bce22eb2416f07b2c31c870a05a | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-Mono-Mono_naive-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.28e-05 | 189 | 155 | 6 | 55aba1ebc012006a5db3ff9c92589cb3d9f7c68a | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 5.28e-05 | 189 | 155 | 6 | 0abc7a4900cc9033bc1be69b770ccc54a6bf41b4 | |
| ToppCell | PCW_05-06-Epithelial-Epithelial_proliferating-epi_proliferating2_(13)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 5.28e-05 | 189 | 155 | 6 | c8b8f860aaf6c73863cd79941db6b469c830ef06 | |
| ToppCell | LV-06._Ventricular_Cardiomyocyte_II|World / Chamber and Cluster_Paper | 5.43e-05 | 190 | 155 | 6 | de5ef606a002f85c2e0e3a36c1f259d0b85a76ff | |
| ToppCell | 10x_3'_v3-spleen_(10x_3'_v3)-myeloid-myeloid_monocytic-intermediate_monocyte|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 5.43e-05 | 190 | 155 | 6 | 896b5825edb30fe62cbbed6078570c1f8057a99e | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 5.59e-05 | 191 | 155 | 6 | d0e9afe7b6334dd515d3e68892efdc76347a55e5 | |
| ToppCell | Control-Stromal_mesenchymal|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.59e-05 | 191 | 155 | 6 | 14057205ddb9b4bbc582d1358d13cf36d979a61b | |
| ToppCell | LPS_only-Stromal_mesenchymal-Lung_smooth_muscle|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.59e-05 | 191 | 155 | 6 | 08042952431ca1a6fd7dfc13f36eb28643979598 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_fibro-stroma-endosteal_fibroblast|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.59e-05 | 191 | 155 | 6 | 44b1f62fdee03b157fe545f2ae6ff84f8929a8ac | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)|10x_3'_v3 / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 5.76e-05 | 192 | 155 | 6 | 072281344d58e85c9a290750b488d0c101f75d54 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_myocytic|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 6.10e-05 | 194 | 155 | 6 | 67f5e2f05a8de2213ab80d5ea16fdee121684633 | |
| ToppCell | Healthy-Classical_Monocyte|World / disease group, cell group and cell class | 6.27e-05 | 195 | 155 | 6 | 0d96f456cc84ebb2543406fb2374c6d7cedd3c4d | |
| ToppCell | COVID-19-Heart-CM_2|Heart / Disease (COVID-19 only), tissue and cell type | 6.27e-05 | 195 | 155 | 6 | 75fc81bddb246dca3b437fb60827b1d4fe416405 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 6.27e-05 | 195 | 155 | 6 | 3d6d3de8ada6dce3dc789c15b50cc066e7100496 | |
| ToppCell | Healthy-Classical_Monocyte|Healthy / disease group, cell group and cell class | 6.45e-05 | 196 | 155 | 6 | 27d24aa2fd4521cf7e410688ed3b11b2d9700dd2 | |
| ToppCell | facs-Bladder-nan-3m|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-05 | 196 | 155 | 6 | 44f5b1b474399c9316729155f2ea95a82ca66e30 | |
| ToppCell | myeloid|World / Lineage and Cell class | 6.45e-05 | 196 | 155 | 6 | c76af19827917b9f64ed9fff449f34d04e080a2a | |
| ToppCell | Bronchial-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.45e-05 | 196 | 155 | 6 | 9830fb3da7a60f65ad463e9054bb77c06b025e4d | |
| ToppCell | facs-Bladder-nan-3m-Epithelial|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-05 | 196 | 155 | 6 | c0e90d964baa2eb4fbd18a52379ccec5d3bf59a8 | |
| ToppCell | Frontal_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn.Inmt_(Inmt)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 6.55e-05 | 121 | 155 | 5 | 5035e071033cb76a7fc0128716755b14821e8f05 | |
| ToppCell | Frontal_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn.Inmt_(Inmt)-|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 6.55e-05 | 121 | 155 | 5 | c96115bd33455296378a257583b49442d00b39ca | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Hematopoietic-Myeloid-Macrophages|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.64e-05 | 197 | 155 | 6 | 10190b877bf46ba2163d203df9dd3b498c66e52f | |
| ToppCell | severe-unassigned|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 6.64e-05 | 197 | 155 | 6 | 70704b149b2820b8601d2495b7cd9cbe91eda262 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Myeloid-Monocytic-Classical_Monocyte-Mono_c2-CD14-HLA-DPB1|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.64e-05 | 197 | 155 | 6 | 321ccd20b0bb03c99a00452ac3c637ee3aa73ecf | |
| ToppCell | PBMC-Convalescent-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_2|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 6.64e-05 | 197 | 155 | 6 | 6e96a6c2576f52b72aeab1e41f47a0af05ff327a | |
| ToppCell | PBMC-Convalescent-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_2|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 6.64e-05 | 197 | 155 | 6 | a80be1081f3ed0aceea69a33be21bca6bc354472 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Myeloid-Monocytic-Classical_Monocyte-Mono_c3-CD14-VCAN|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.64e-05 | 197 | 155 | 6 | 928d70af7b990300be69a4debce6e66b556e5d9f | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Myeloid-Monocytic-Classical_Monocyte|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.64e-05 | 197 | 155 | 6 | 0050da0d809075fde3a7f17894dbb410b254988c | |
| ToppCell | mild_COVID-19-Classical_Monocyte|World / disease group, cell group and cell class (v2) | 6.64e-05 | 197 | 155 | 6 | 5d826f4d7b7a46847c67e6bef38eb860bc808a6c | |
| ToppCell | distal-3-mesenchymal-Fibromyocyte|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 6.83e-05 | 198 | 155 | 6 | dc93886439a378a0c71e99acb8081bfb6b6d467b | |
| ToppCell | PBMC-Control-Myeloid-cDC-cDC-cDC_0|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 6.83e-05 | 198 | 155 | 6 | c1fe38594bd6292fcc60bdbb563376b454731d00 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Myeloid-Monocytic|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.83e-05 | 198 | 155 | 6 | 4d70995b4dd6365b0c3cda3663a82efdb4870d19 | |
| ToppCell | ILEUM-inflamed-(3)_MNP-(3)_Resident_macrophages|(3)_MNP / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 6.83e-05 | 198 | 155 | 6 | 30bf78d4d657cf5140549d3dbf43d4f00482e300 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Myeloid|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.83e-05 | 198 | 155 | 6 | 2a361af16bf6ecec12f22bdf7926afc7e5ad45ae | |
| ToppCell | 10x3'2.3-week_12-13-Myeloid_neutrophil-granulo-neutrophil-myelocyte|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 6.83e-05 | 198 | 155 | 6 | c65103828a4755fcf3c0776c60d8ada1f0ad5278 | |
| Drug | Adenosine Triphosphate | 7.18e-07 | 193 | 152 | 10 | ctd:D000255 | |
| Drug | Utedrin | 1.81e-06 | 14 | 152 | 4 | CID000005771 | |
| Drug | Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A | 7.32e-06 | 197 | 152 | 9 | 2654_UP | |
| Drug | Antipyrine, 4-hydroxy [1672-63-5]; Down 200; 19.6uM; PC3; HG-U133A | 8.27e-06 | 200 | 152 | 9 | 1915_DN | |
| Drug | AC1L1IPV | 9.74e-06 | 43 | 152 | 5 | CID000004683 | |
| Drug | JTP 4819 | 3.38e-05 | 10 | 152 | 3 | ctd:C094211 | |
| Drug | N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo(3,2-d)pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide | 4.43e-05 | 2 | 152 | 2 | ctd:C570404 | |
| Drug | AC1NURZQ | 4.43e-05 | 2 | 152 | 2 | CID005490952 | |
| Drug | N-alpha-(2-carboxyl)benzoyl-N5-(2-chloro-1-iminoethyl)ornithine amide | 4.43e-05 | 2 | 152 | 2 | ctd:C568520 | |
| Drug | Lapatinib | 4.43e-05 | 2 | 152 | 2 | DB01259 | |
| Drug | 2-phenylalanine | 4.43e-05 | 2 | 152 | 2 | CID000031722 | |
| Drug | Cgp 29325 | 4.43e-05 | 2 | 152 | 2 | CID000175772 | |
| Drug | Glumitocin | 4.43e-05 | 2 | 152 | 2 | CID003084054 | |
| Drug | Demoxytocin | 4.43e-05 | 2 | 152 | 2 | CID000008229 | |
| Drug | octyldodecanol | 4.43e-05 | 2 | 152 | 2 | CID000021414 | |
| Drug | P9-28 | 4.43e-05 | 2 | 152 | 2 | CID000139428 | |
| Drug | Pro-arg-gly-amide | 4.43e-05 | 2 | 152 | 2 | CID000170777 | |
| Drug | oryzalin | 4.43e-05 | 2 | 152 | 2 | ctd:C012465 | |
| Drug | 5-carboxymethyluridine | 4.43e-05 | 2 | 152 | 2 | CID003080720 | |
| Drug | Phasvatocin | 4.43e-05 | 2 | 152 | 2 | CID000192334 | |
| Drug | ethyl cyclohexylideneacetate | 4.43e-05 | 2 | 152 | 2 | CID000073776 | |
| Drug | AC1L1GHE | 4.53e-05 | 96 | 152 | 6 | CID000003684 | |
| Drug | Labetalol hydrochloride [32780-64-6]; Up 200; 11uM; MCF7; HT_HG-U133A | 4.77e-05 | 193 | 152 | 8 | 6809_UP | |
| Drug | Citalopram hydrobromide [59729-32-7]; Down 200; 1uM; MCF7; HT_HG-U133A | 4.95e-05 | 194 | 152 | 8 | 3903_DN | |
| Drug | Lys-Bradykinin | 5.04e-05 | 60 | 152 | 5 | CID000009569 | |
| Drug | Adiphenine hydrochloride [50-42-0]; Up 200; 11.4uM; MCF7; HT_HG-U133A | 5.13e-05 | 195 | 152 | 8 | 7037_UP | |
| Drug | (-)-depudecin; Up 200; 1uM; MCF7; HT_HG-U133A_EA | 5.13e-05 | 195 | 152 | 8 | 874_UP | |
| Drug | Lomefloxacin hydrochloride [98079-52-8]; Up 200; 10.4uM; MCF7; HT_HG-U133A | 5.32e-05 | 196 | 152 | 8 | 2310_UP | |
| Drug | Flavoxate hydrochloride [3717-88-2]; Down 200; 9.4uM; HL60; HT_HG-U133A | 5.32e-05 | 196 | 152 | 8 | 2373_DN | |
| Drug | Mevalonic-D, L acid lactone [674-26-0]; Up 200; 30.8uM; MCF7; HT_HG-U133A | 5.52e-05 | 197 | 152 | 8 | 3459_UP | |
| Drug | estradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A | 5.52e-05 | 197 | 152 | 8 | 5238_DN | |
| Drug | (1)-Nipecotic acid [498-95-3]; Down 200; 31uM; MCF7; HT_HG-U133A | 5.52e-05 | 197 | 152 | 8 | 5999_DN | |
| Drug | Fenspiride hydrochloride [5053-08-7]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 5.72e-05 | 198 | 152 | 8 | 6001_UP | |
| Drug | Sisomicin sulfate [53179-09-2]; Up 200; 2.8uM; MCF7; HT_HG-U133A | 5.72e-05 | 198 | 152 | 8 | 4132_UP | |
| Drug | Bupropion hydrochloride [31677-93-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A | 5.72e-05 | 198 | 152 | 8 | 3180_UP | |
| Drug | Ethisterone [434-03-7]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 5.72e-05 | 198 | 152 | 8 | 2326_UP | |
| Drug | Adrenosterone [382-45-6]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 5.72e-05 | 198 | 152 | 8 | 5464_UP | |
| Drug | Finasteride [98319-26-7]; Down 200; 10.8uM; MCF7; HT_HG-U133A | 5.92e-05 | 199 | 152 | 8 | 6062_DN | |
| Drug | Ald1.1-H_000455; Up 200; 10uM; MCF7; HT_HG-U133A | 5.92e-05 | 199 | 152 | 8 | 7516_UP | |
| Drug | AC1L1KC5 | HIF1A AVP GRM2 HPSE RYR2 TG OXT EGFR TRPV2 AHR EEF2K IL2RB CRTAP | 7.22e-05 | 541 | 152 | 13 | CID000005428 |
| Drug | phorone | 7.90e-05 | 106 | 152 | 6 | ctd:C018637 | |
| Drug | 2-thiazolylethylamine | 1.01e-04 | 14 | 152 | 3 | CID000087653 | |
| Drug | Nicardipine | 1.31e-04 | 39 | 152 | 4 | ctd:D009529 | |
| Drug | ranatensin C | 1.32e-04 | 3 | 152 | 2 | CID005488559 | |
| Drug | Annetocin | 1.32e-04 | 3 | 152 | 2 | CID000197651 | |
| Drug | PJ34 hydrochloride hydrate | 1.32e-04 | 3 | 152 | 2 | CID000004858 | |
| Drug | N-alpha-(2-carboxyl)benzoyl-N5-(2-fluoro-1-iminoethyl)ornithine amide | 1.32e-04 | 3 | 152 | 2 | ctd:C568519 | |
| Drug | L 366682 | 1.32e-04 | 3 | 152 | 2 | CID000196819 | |
| Drug | Dibutyryl Cyclic GMP | 1.32e-04 | 3 | 152 | 2 | ctd:D003995 | |
| Drug | pyrido[3,4-d]pyrimidine | 1.32e-04 | 3 | 152 | 2 | CID014758064 | |
| Drug | 5-iodonicotinic acid | 1.32e-04 | 3 | 152 | 2 | CID000151950 | |
| Drug | AC1O4Q3H | 1.32e-04 | 3 | 152 | 2 | CID006410744 | |
| Drug | 2-acetamidoethanethiol | 1.32e-04 | 3 | 152 | 2 | ctd:C023704 | |
| Drug | L 366811 | 1.32e-04 | 3 | 152 | 2 | CID003083084 | |
| Drug | 4557 W | 1.32e-04 | 3 | 152 | 2 | ctd:C433938 | |
| Drug | dE-Vvt | 1.32e-04 | 3 | 152 | 2 | CID003083171 | |
| Drug | AC1L45X9 | 1.32e-04 | 3 | 152 | 2 | CID000151233 | |
| Drug | D-3250 | 1.32e-04 | 3 | 152 | 2 | CID004124837 | |
| Drug | Dglvp | 1.32e-04 | 3 | 152 | 2 | CID000169434 | |
| Drug | 4-aminopyrimidine-5-carbaldehyde | 1.32e-04 | 3 | 152 | 2 | CID011228787 | |
| Drug | Asvatocin | 1.32e-04 | 3 | 152 | 2 | CID000192333 | |
| Drug | AC1Q5THZ | HIF1A AVP PARP3 HPSE TIPARP TG CKMT2 OXT NFATC3 AHR IL2RB PADI1 | 1.45e-04 | 502 | 152 | 12 | CID000001959 |
| Drug | azar | 1.47e-04 | 75 | 152 | 5 | CID000015967 | |
| Drug | 2,3,4,7,8-pentachlorodibenzofuran | 1.47e-04 | 75 | 152 | 5 | ctd:C038890 | |
| Disease | mental development measurement | 7.08e-06 | 25 | 148 | 4 | EFO_0008230 | |
| Disease | Infantile nystagmus | 2.50e-05 | 2 | 148 | 2 | C2673809 | |
| Disease | Dysmenorrhea | 2.50e-05 | 2 | 148 | 2 | C0013390 | |
| Disease | Alcoholic Intoxication, Chronic | 6.57e-05 | 268 | 148 | 8 | C0001973 | |
| Disease | Tachycardia | 9.55e-05 | 18 | 148 | 3 | C0039231 | |
| Disease | Tachyarrhythmia | 9.55e-05 | 18 | 148 | 3 | C0080203 | |
| Disease | Hyponatremia | 1.49e-04 | 4 | 148 | 2 | C0020625 | |
| Disease | Sarcosine measurement | 2.03e-04 | 23 | 148 | 3 | EFO_0021668 | |
| Disease | Polyuria | 2.47e-04 | 5 | 148 | 2 | C0032617 | |
| Disease | level of Phosphatidylcholine (O-16:0_16:1) in blood serum | 2.47e-04 | 5 | 148 | 2 | OBA_2045112 | |
| Disease | Cetuximab response | 2.47e-04 | 5 | 148 | 2 | cv:CN077967 | |
| Disease | Panitumumab response | 2.47e-04 | 5 | 148 | 2 | cv:CN077999 | |
| Disease | urate measurement, bone density | SEC31A TIPARP DNAH1 TG PLXNA4 CD302 EIF2AK4 UTRN CDH12 MPPED1 CRTAP | 3.04e-04 | 619 | 148 | 11 | EFO_0003923, EFO_0004531 |
| Disease | ocular sarcoidosis | 3.04e-04 | 116 | 148 | 5 | EFO_0010723 | |
| Disease | colorectal cancer (is_implicated_in) | 3.70e-04 | 121 | 148 | 5 | DOID:9256 (is_implicated_in) | |
| Disease | oxytocin-neurophysin 1 measurement | 3.70e-04 | 6 | 148 | 2 | EFO_0802839 | |
| Disease | level of Phosphatidylcholine (18:2_18:2) in blood serum | 3.70e-04 | 6 | 148 | 2 | OBA_2045106 | |
| Disease | Hypertensive disease | 4.07e-04 | 190 | 148 | 6 | C0020538 | |
| Disease | childhood trauma measurement, alcohol consumption measurement | 4.55e-04 | 71 | 148 | 4 | EFO_0007878, EFO_0007979 | |
| Disease | serum lipopolysaccharide activity | 5.16e-04 | 7 | 148 | 2 | EFO_0600064 | |
| Disease | Acute lymphocytic leukemia | 5.16e-04 | 7 | 148 | 2 | C0023449 | |
| Disease | chronotype measurement | DOCK3 TFEC CA14 DNAH1 RGL1 KMT2D FAM193A NFATC3 PLXNA4 PKHD1 TSHZ1 CFAP61 ANKFN1 | 5.21e-04 | 882 | 148 | 13 | EFO_0008328 |
| Disease | intestinal cancer (implicated_via_orthology) | 5.51e-04 | 32 | 148 | 3 | DOID:10155 (implicated_via_orthology) | |
| Disease | myelofibrosis (is_implicated_in) | 6.86e-04 | 8 | 148 | 2 | DOID:4971 (is_implicated_in) | |
| Disease | serum albumin measurement | DOCK3 SH2B3 RASA3 ZZEF1 TBC1D13 ALDH1A2 TBC1D10A LPA EIF2AK4 SH2D7 | 8.42e-04 | 592 | 148 | 10 | EFO_0004535 |
| Disease | vitamin D deficiency | 8.48e-04 | 37 | 148 | 3 | EFO_0003762 | |
| Disease | Erythrocytosis familial, 1 | 8.79e-04 | 9 | 148 | 2 | C4551637 | |
| Disease | Autosomal Recessive Polycystic Kidney Disease | 8.79e-04 | 9 | 148 | 2 | C0085548 | |
| Disease | kynurenine measurement | 9.90e-04 | 39 | 148 | 3 | EFO_0008529 | |
| Disease | Head and Neck Carcinoma | 1.10e-03 | 10 | 148 | 2 | C3887461 | |
| Disease | Prostatic Neoplasms | 1.14e-03 | 616 | 148 | 10 | C0033578 | |
| Disease | Malignant neoplasm of prostate | 1.14e-03 | 616 | 148 | 10 | C0376358 | |
| Disease | high grade glioma (is_implicated_in) | 1.23e-03 | 42 | 148 | 3 | DOID:3070 (is_implicated_in) | |
| Disease | gallbladder neoplasm | 1.33e-03 | 11 | 148 | 2 | C0016978 | |
| Disease | brain infarction (implicated_via_orthology) | 1.33e-03 | 11 | 148 | 2 | DOID:3454 (implicated_via_orthology) | |
| Disease | Malignant neoplasm of gallbladder | 1.33e-03 | 11 | 148 | 2 | C0153452 | |
| Disease | Disease Exacerbation | 1.50e-03 | 165 | 148 | 5 | C0235874 | |
| Disease | autoimmune thyroiditis (is_implicated_in) | 1.60e-03 | 12 | 148 | 2 | DOID:7188 (is_implicated_in) | |
| Disease | Papilloma | 1.60e-03 | 12 | 148 | 2 | C0030354 | |
| Disease | Papillomatosis | 1.60e-03 | 12 | 148 | 2 | C0205875 | |
| Disease | Papilloma, Squamous Cell | 1.60e-03 | 12 | 148 | 2 | C0205874 | |
| Disease | Acute kidney injury | 1.70e-03 | 101 | 148 | 4 | C2609414 | |
| Disease | Acute Kidney Insufficiency | 1.70e-03 | 101 | 148 | 4 | C1565662 | |
| Disease | Kidney Failure, Acute | 1.70e-03 | 101 | 148 | 4 | C0022660 | |
| Disease | phosphoglycerides measurement | 1.81e-03 | 48 | 148 | 3 | EFO_0022291 | |
| Disease | Pain, Migratory | 1.92e-03 | 49 | 148 | 3 | C0751407 | |
| Disease | Suffering, Physical | 1.92e-03 | 49 | 148 | 3 | C0751408 | |
| Disease | Pain, Crushing | 1.92e-03 | 49 | 148 | 3 | C0458259 | |
| Disease | Pain, Splitting | 1.92e-03 | 49 | 148 | 3 | C0458257 | |
| Disease | Pain | 1.92e-03 | 49 | 148 | 3 | C0030193 | |
| Disease | Radiating pain | 1.92e-03 | 49 | 148 | 3 | C0234254 | |
| Disease | Pain, Burning | 1.92e-03 | 49 | 148 | 3 | C0234230 | |
| Disease | Ache | 1.92e-03 | 49 | 148 | 3 | C0234238 | |
| Disease | hepatocellular carcinoma (implicated_via_orthology) | 1.92e-03 | 49 | 148 | 3 | DOID:684 (implicated_via_orthology) | |
| Disease | Unipolar Depression | 2.01e-03 | 259 | 148 | 6 | C0041696 | |
| Disease | Neoplasm of lung | 2.19e-03 | 14 | 148 | 2 | cv:C0024121 | |
| Disease | median neuropathy (biomarker_via_orthology) | 2.19e-03 | 14 | 148 | 2 | DOID:571 (biomarker_via_orthology) | |
| Disease | Lung cancer | 2.19e-03 | 14 | 148 | 2 | cv:C0242379 | |
| Disease | LUNG CANCER | 2.19e-03 | 14 | 148 | 2 | 211980 | |
| Disease | lysophosphatidylcholine 15:0 measurement | 2.19e-03 | 14 | 148 | 2 | EFO_0020941 | |
| Disease | Birth Weight | 2.19e-03 | 14 | 148 | 2 | C0005612 | |
| Disease | monokine induced by gamma interferon measurement | 2.28e-03 | 52 | 148 | 3 | EFO_0008236 | |
| Disease | Neoplasm Invasiveness | 2.41e-03 | 184 | 148 | 5 | C0027626 | |
| Disease | Hypotension | 2.41e-03 | 53 | 148 | 3 | C0020649 | |
| Disease | total phospholipids in lipoprotein particles measurement | 2.41e-03 | 53 | 148 | 3 | EFO_0022315 | |
| Disease | tumor necrosis factor measurement | 2.51e-03 | 15 | 148 | 2 | EFO_0010834 | |
| Disease | triglycerides to total lipids in chylomicrons and extremely large VLDL percentage | 2.51e-03 | 15 | 148 | 2 | EFO_0022328 | |
| Disease | Diffuse Large B-Cell Lymphoma | 2.68e-03 | 55 | 148 | 3 | C0079744 | |
| Disease | triglycerides in very large HDL measurement | 2.68e-03 | 55 | 148 | 3 | EFO_0022324 | |
| Disease | response to calcium channel blocker | 2.82e-03 | 56 | 148 | 3 | EFO_0007767 | |
| Disease | cholesteryl esters to total lipids in medium HDL percentage | 2.82e-03 | 56 | 148 | 3 | EFO_0022251 | |
| Disease | decreased susceptibility to hepatitis C infection | 2.86e-03 | 16 | 148 | 2 | EFO_0010101 | |
| Disease | lymphocyte measurement | 2.91e-03 | 117 | 148 | 4 | EFO_0803546 | |
| Disease | prostate cancer (is_implicated_in) | 2.91e-03 | 117 | 148 | 4 | DOID:10283 (is_implicated_in) | |
| Disease | Multiple congenital anomalies | 3.23e-03 | 17 | 148 | 2 | C0000772 | |
| Disease | cholesterol to total lipids in chylomicrons and extremely large VLDL percentage | 3.23e-03 | 17 | 148 | 2 | EFO_0022232 | |
| Disease | factor XI measurement, Ischemic stroke | 3.23e-03 | 17 | 148 | 2 | EFO_0004694, HP_0002140 | |
| Disease | maximum cigarettes per day measurement | 3.63e-03 | 18 | 148 | 2 | EFO_0009264 | |
| Disease | peritonsillar abscess | 3.63e-03 | 18 | 148 | 2 | EFO_0007429 | |
| Disease | oral squamous cell carcinoma (is_marker_for) | 3.94e-03 | 63 | 148 | 3 | DOID:0050866 (is_marker_for) | |
| Disease | diet measurement, HOMA-B | 4.04e-03 | 19 | 148 | 2 | EFO_0004469, EFO_0008111 | |
| Disease | laryngeal squamous cell carcinoma (is_marker_for) | 4.04e-03 | 19 | 148 | 2 | DOID:2876 (is_marker_for) | |
| Disease | cerebral infarction (is_marker_for) | 4.04e-03 | 19 | 148 | 2 | DOID:3526 (is_marker_for) | |
| Disease | carcinoma (implicated_via_orthology) | 4.12e-03 | 64 | 148 | 3 | DOID:305 (implicated_via_orthology) | |
| Disease | exercise test | 4.47e-03 | 20 | 148 | 2 | EFO_0004328 | |
| Disease | Neoplasms, Experimental | 4.49e-03 | 66 | 148 | 3 | C0027659 | |
| Disease | platelet component distribution width | TFEC GAPVD1 SH2B3 RASA3 ZZEF1 TBC1D10A EGFR ZBTB10 EIF2AK4 LTBR | 4.90e-03 | 755 | 148 | 10 | EFO_0007984 |
| Disease | saturated fatty acids to total fatty acids percentage | 4.93e-03 | 21 | 148 | 2 | EFO_0022305 | |
| Disease | free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage | 4.93e-03 | 21 | 148 | 2 | EFO_0022277 | |
| Disease | cholesteryl esters to total lipids in chylomicrons and extremely large VLDL percentage | 4.93e-03 | 21 | 148 | 2 | EFO_0022246 | |
| Disease | docosahexaenoic acid to total fatty acids percentage | 4.93e-03 | 21 | 148 | 2 | EFO_0022262 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TNIELLVCNYEPPGN | 156 | Q6UXB8 | |
| NSCPVPNTYTNVIEN | 1176 | Q5DID0 | |
| YTPCLNQFPQELNVG | 1066 | Q9UPW8 | |
| EEATGLPQTVVCYNP | 191 | P35869 | |
| GLNPQSAIITPQTCY | 751 | P35869 | |
| LENAPCYDNVPQGIF | 1011 | Q6ZRH7 | |
| LTCSPQPEYVNQPDV | 1131 | P04626 | |
| TGQQYQVPCPTEADI | 771 | Q8NHU2 | |
| EPPLVDQTVPQCYSE | 1021 | Q9NP73 | |
| LSQGQECGEYPVTIP | 491 | Q9P2K8 | |
| GQCAVANQQYVPEPN | 121 | Q96Q42 | |
| PVYNPATGEQVCEVQ | 56 | O94788 | |
| TRNDVGPYECEIQNP | 206 | P31997 | |
| GPYECEIQNPASANF | 211 | P31997 | |
| STAPQSPYNEDCVLV | 206 | Q8IX05 | |
| PNASLTGCFELPQEY | 546 | Q14416 | |
| NPSNPYCNGIQGIVE | 366 | O75131 | |
| DQNSVDCPQLYKPGQ | 931 | Q8TF62 | |
| IGPYECEIQNPVGAS | 211 | Q14002 | |
| NEATCISVPPVDGYV | 631 | O94985 | |
| LLPCYNIQVSVAQGP | 1646 | Q6W2J9 | |
| CPGYITVVSVSNNPV | 331 | Q6ZW61 | |
| PSYPTQQAEQAPNTC | 396 | P78312 | |
| NVNAYEECPSGIPID | 61 | Q9H8W3 | |
| NVNNTCFPQLTPGEE | 76 | Q8IZY2 | |
| NGEQEVPNESCYPSR | 1056 | Q09MP3 | |
| PQPNYADTLISQESC | 771 | Q9Y5H1 | |
| PQCLSYEVERQPGEQ | 231 | Q9ULC6 | |
| GLPIVNGQCDPYATV | 156 | Q14644 | |
| PPYSFIDCSVNIGLN | 221 | Q9H0N0 | |
| PPYSFIDCSVNIGLN | 221 | Q53S08 | |
| TVLPPVYNQQNEDTC | 636 | Q9NZL6 | |
| SNFVEQIPDSYIPGC | 891 | A6NNM3 | |
| PSVSDQPGEKENCYQ | 1301 | A6NNM3 | |
| SNFVEQIPDSYIPGC | 891 | A6NJZ7 | |
| PSVSDQPGEKENCYQ | 1301 | A6NJZ7 | |
| SEPVVQCQYPSGAEA | 431 | P78412 | |
| QIICPDGVTSANFYP | 436 | Q7Z3E1 | |
| TCPLSSNPGTQVYED | 51 | Q9Y6F1 | |
| NTQPPQEVYACSIFE | 301 | Q9UM07 | |
| QPQTYQICLVDPVSG | 516 | Q9H2M9 | |
| STNFGECPIPDYQEQ | 826 | Q96QZ7 | |
| GCIPSNYVAPVDSIQ | 126 | P09769 | |
| NSAAVVPAQYICAPD | 1786 | Q4ZG55 | |
| YQDNQPCLDLIEGSP | 466 | Q96H55 | |
| GLPQLTSYDCEVNAP | 791 | Q16665 | |
| TDVPYIPCTGQQVGI | 476 | Q6ZUT3 | |
| CPAVVNPEQYGIISD | 316 | Q14C86 | |
| IVTETYGNADPCVQP | 906 | Q86SJ6 | |
| YGNADPCVQPTTIIF | 911 | Q86SJ6 | |
| APVYDIQGNICVPAE | 941 | Q86SJ6 | |
| SEYTQPTPIQCQGVP | 271 | Q86XP3 | |
| AQYPGVCINNEVVEP | 76 | P50135 | |
| NLPQPQSGQRGYECV | 726 | O75051 | |
| NALQYETVQVVDPGP | 466 | Q9HCM2 | |
| NLPQPQSGQRGYECI | 726 | Q9HCM2 | |
| GPNELDNFYCDVPQV | 171 | Q8NH05 | |
| PQPNYADTLISQQSC | 771 | Q9Y5G4 | |
| YTCQVKNPPDVDGVI | 121 | O60487 | |
| PDGKTCRQNSNIEPY | 3186 | P98164 | |
| AVPPGEEQRYTCQVE | 271 | Q30201 | |
| NPCGAIVTGYTDQQP | 851 | Q9P2E7 | |
| NASVCTVNYQPVNPP | 301 | O15442 | |
| EVGYSIPQEDCTGPN | 126 | Q8TE96 | |
| QVNQDICKYGSIPPD | 121 | Q9Y251 | |
| GTPEEPCQEAFNQTN | 66 | O95867 | |
| QCGAETYQPIQSPTF | 186 | P33993 | |
| RCQNAYIATQGPLPE | 1456 | Q13332 | |
| DYIATQGPLQNTCQD | 966 | Q16825 | |
| PQPNYADTLISQESC | 771 | Q9Y5H0 | |
| PPGTLCVLYAEGQEN | 746 | Q5K4E3 | |
| PPSELNSVEYKCEQG | 1656 | Q9BXP8 | |
| LFNCLVYGPENTQPI | 471 | Q7L622 | |
| EAPSELTQRPQVGCY | 4151 | Q9P2D7 | |
| PEYLNTVQPTCVNST | 1136 | P00533 | |
| PQDIQALAYGLCPTQ | 1851 | Q14674 | |
| DYNGCPNIPSSLIFQ | 571 | Q8IZD9 | |
| QNPGPDTYCVIAGSE | 691 | P49917 | |
| QCVYFLPQEEPVVQG | 316 | Q9NVM4 | |
| TRNDTGPYECEIQNP | 206 | P13688 | |
| GPYECEIQNPVSANR | 211 | P13688 | |
| QCEENLTPVIGGYPV | 276 | O75718 | |
| SPEQVLQPLEGDLCY | 191 | Q8TDQ1 | |
| VVVPVANCGVQEYNS | 136 | Q9H9V9 | |
| TPQTCYPNNEIGILD | 821 | Q9HC77 | |
| TDAPQCPQGTLQVYE | 1471 | P29400 | |
| QPLQPLSGEDDAYCT | 406 | P14784 | |
| IYSTGKVCNPDNPQE | 126 | Q9BYF1 | |
| EQAPTEQRPGVQECY | 471 | P08519 | |
| EQAPTEQSPTVQDCY | 1261 | P08519 | |
| QGPDCSLNVPSTESY | 276 | Q5VV63 | |
| YECVGTCQQPPEALA | 291 | O00292 | |
| EQVPCLNSEYGCPLS | 61 | Q9UH90 | |
| PDLPYICTAQNPVSQ | 216 | Q9HBG7 | |
| LLSVEPTDQGCYPLN | 341 | Q8WUP2 | |
| CQITPAEGPVVTAQY | 126 | P01042 | |
| VPYETAVCENAKPGQ | 491 | P55289 | |
| TAPACSQVPLQDYQS | 341 | Q9BV79 | |
| GYFICPITDDPSSNQ | 36 | O00418 | |
| SLPEASVVCPNQDYN | 246 | Q5W0V3 | |
| SYPECGNNAQSPIDI | 36 | Q9ULX7 | |
| QPEGTYGEQLVPELC | 546 | A0AV02 | |
| EGQQESPPKNYLCIE | 586 | Q9ULF5 | |
| TEYIQGPCTGNQQSL | 3921 | Q92736 | |
| NQETPSQQVGPQCSY | 161 | A0A1W2PPM1 | |
| QNQDPSIPYADCLTQ | 86 | P47887 | |
| VISDPSNCSQYPDIV | 271 | Q03933 | |
| TPNGYTLDQCIQTGV | 81 | P17540 | |
| FVLYPLQNGSAPCTE | 561 | Q9UN66 | |
| PQPNYADTLISQESC | 771 | Q9Y5H4 | |
| YQVCDIPQPQGSIIN | 111 | O14896 | |
| QNQDPSIPYADCLTQ | 86 | P30953 | |
| DLYDENVCQPGAPSI | 331 | P09001 | |
| IPCNVSDYDGPSEQN | 41 | Q9P2B2 | |
| NIVSAAPCQAEPQQY | 56 | O75529 | |
| APCQAEPQQYEVQFG | 61 | O75529 | |
| TEQAVACSLPQSPEY | 446 | Q4G112 | |
| QYCQTLGGESPVSQP | 3231 | P46939 | |
| SPPACQATEDVDYTQ | 101 | Q6ZWK4 | |
| LQYAGPVPALTQACQ | 886 | Q9UPZ6 | |
| SNFVEQIPDSYIPGC | 891 | Q9UFD9 | |
| LPSVTRNETGPYQCE | 296 | Q00889 | |
| QEENYLPSPCQSGQK | 76 | P01178 | |
| VCTGVYNPRNPQSTE | 361 | Q9BXW7 | |
| IIDNSQGFYVCPVEP | 281 | Q9Y617 | |
| ICAPGAPAQQVYLQE | 3981 | P08F94 | |
| ASDDVCTAPGQNNPY | 726 | Q8N957 | |
| DDPCYINTQALQSTP | 461 | Q6S5L8 | |
| TCNEPQAYNDAITPR | 341 | Q9UL52 | |
| PVCANYSIDTLQPVG | 151 | Q9H3T3 | |
| FLTGVLCSYPNPNED | 66 | Q8IY95 | |
| PVYCGNEVTPTEAAQ | 186 | Q96DV4 | |
| INGNPCADLTYPEVI | 56 | Q9UMS6 | |
| QELTPGEPQYCQYGT | 1746 | Q15772 | |
| CQYGTPEFVAPEIVN | 1756 | Q15772 | |
| ICFPGYVPNSAVLQQ | 1041 | A6NE52 | |
| QEENYLPSPCQSGQK | 76 | P01185 | |
| GNPQPLVNAQCTDDY | 146 | Q9Y5S1 | |
| IQPEILDGPNQYFCE | 351 | Q96K76 | |
| QTNVVYNGPTCLPIN | 806 | Q12968 | |
| ETEYPVKIVNTPQGC | 676 | O43847 | |
| YVVVVSQPPGSCNTV | 461 | Q9UQQ2 | |
| TPDQEGSTYEQIPAC | 366 | A6NKC9 | |
| FSQLQGYQPCDPQVI | 601 | Q9H254 | |
| PSSLNEYEVLPNGCE | 191 | Q9NVG8 | |
| NGVAVTEYDPQPAIQ | 1071 | O60290 | |
| QAVPPYASENQTCRD | 31 | P36941 | |
| ENETLYENNECGKPP | 241 | Q9UJW8 | |
| EPDNAQEYGCVQQPK | 26 | O95789 | |
| QGAVEYPDPIAQKTC | 831 | O43592 | |
| QSEPAQNFCGPYSEL | 1296 | O43149 | |
| ASPCPQVYLEVPQEE | 76 | P0C7W0 | |
| YCQQLTVSQGPSPEL | 261 | O14948 | |
| YNIPPNNETNLEDCS | 586 | Q96DT7 | |
| ASQPVERANPEGLCY | 331 | Q96S15 | |
| QECNCRPQESPYVSG | 716 | Q9UJV3 | |
| VTPDQITCSNPEQYV | 76 | O15537 | |
| LCSNPNTGEVLYELP | 286 | O94979 | |
| PTYTEVDPCILNNNV | 376 | Q9H3M7 | |
| PEEGYCQAQAPIAAV | 191 | Q9BXI6 | |
| QVQCNGPPEQVFELY | 771 | P01266 | |
| QCPDSVSYPQDSLAQ | 101 | Q6ZSZ6 | |
| ETSQPYEEVSQPCQE | 1246 | Q6PFW1 | |
| EYCSTIPPLQQAQAS | 781 | O95405 | |
| LAICSQNQPPYETIP | 36 | Q5R3F8 | |
| PTDEPDALYVACQGQ | 381 | O14686 | |
| NQISYTPQDPRDLCG | 396 | Q6IA69 |